 -- Presented Data at 53 rd Annual Meeting of the American Society of Nephrology ASN Highlighting Consistent Treatment Effects Across Phase 2 and 3 Clinical Trials of Reloxaliase in E nteric H yperoxaluria EH -- -- Completed Dosing of Subjects in Ph ase 1 Clinical Trial of ALLN-346; Initial Data Expected in the Fourth Quarter of 2020 